IN THE SPECIFICATION

Page 23, replace the third paragraph starting at line 7 with the following:

The kit for the detection of a predisposition to LGMD2 by nucleic acid amplication is also [[in]] within the scope of the invention, such a kit comprises [[a]] at least PCR primers selected from the group of:

- a) [[in]] those described in table Table 1
- b) [[in]] those described in table Table 3
- c) those including the introns-exons junctions on Table 2.
- d) derived from primers defined in a), b) or c).

Page 23, replace the fourth paragraph starting at line 14 with the following:

The nucleic acid sequence of claim 1 to 3 the invention might be inserted in a viral or a retroviral vector, said vector being able to transfect a packaging cell line.

Page 23, replace the sixth paragraph starting at line 18 with the following:

The treatment of LGMD2 disease by gene therapy is implemented by a pharmaceutical composition containing a component selected from the group of:

- a) a nucleic acid sequence according to claims 1-to 4 the invention,
- b) a cell line according to claim 24 the invention.
- c) an aminoacid amino acid sequence according to claims 5 to 9 the invention.